Bio-Techne Corporation (TECH) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Bio-Techne Corporation's CEO, Kim Kelderman, reported that the company's fiscal fourth-quarter organic growth met expectations at 3%, driven by strong double-digit performance in large pharma end markets and proteomic analytical instrumentation. This indicates specific areas of robust growth contributing to the company's stability, despite low single-digit growth in the biotech sector.

Analysis

Bio-Techne Corporation (TECH) delivered fiscal fourth-quarter results that met management's expectations, posting 3% organic growth which was at the high end of its low-single-digit guidance. According to CEO Kim Kelderman, this performance was characterized by a significant divergence across end markets. The large pharma segment was the primary growth engine, delivering double-digit performance that continued a strong trend from the previous quarter. Similarly, the proteomic analytical instrumentation division was a key contributor, returning to double-digit growth and marking its third consecutive quarter of profitability. These strong results, however, were partially offset by weaker performance in the biotech sector, which only achieved low single-digit growth. This composition indicates that while the company is hitting its overall targets, its stability is currently dependent on the outperformance of specific segments to compensate for softness elsewhere.

Key Decisions for Investors

• Investors should closely monitor the sustainability of the double-digit growth momentum in Bio-Techne's large pharma and proteomic instrumentation segments, as these are currently the primary drivers of overall performance.
• Given the reported weakness in the biotech sector, it is prudent to seek further clarity on the outlook for this end market to assess whether the low single-digit growth is a transient headwind or a more persistent drag on future earnings.
• The in-line results suggest operational stability, but the mixed performance across divisions may warrant a hold-and-monitor approach, focusing on whether the company can broaden its growth base beyond its current high-performing segments.